Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease

Trial Profile

Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Basiliximab (Primary) ; Infliximab (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.
    • 28 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.
    • 25 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top